HAVCR2 and acute myeloid leukemia: Several studies have pinpointed TIM-3 as a promising candidate for targeting AML leukemia stem cells, as its higher expression levels were observed on LSCs (defined as CD45+CD34+CD38- [22,86] or Lin-CD34+CD38-CD90- [24]) than on normal HSCs [22,23,24,86,87].